CMX-020 IP

Chimerix is a biopharmaceutical company focused on developing medicines to improve the lives of patients facing deadly diseases. The company's portfolio includes Tembexa (brincidofovir), which received FDA approval for the treatment of smallpox in both adult and pediatric patients. Chimerix is also advancing a clinical-stage pipeline led by ONC201, a small molecule imipridone targeting H3 K27M-mutant gliomas, which has shown promising results in recurrent diffuse midline glioma. The company leverages its expertise in antiviral and oncology drug development to address significant unmet medical needs in infectious diseases and rare cancers.